X4 PHARMACEUTICALS INC. - COMMON STOCK

X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome

05 сен 2023 08:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 сен 2023 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

10 авг 2023 06:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

08 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital

03 авг 2023 08:00:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023

02 авг 2023 08:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 июн 2023 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Expected to Join Russell 3000® Index

13 июн 2023 08:00:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 июн 2023 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

16 май 2023 16:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market

16 май 2023 08:30:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update

04 май 2023 06:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023

26 апр 2023 08:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 апр 2023 16:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

21 мар 2023 06:05:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023

07 мар 2023 08:01:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 мар 2023 16:05:01 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals’ Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

12 дек 2022 08:30:00 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Prices $65.0 Million Public Offering

07 дек 2022 08:43:05 Источник Nasdaq GlobeNewswire

X4 Pharmaceuticals Announces Proposed Public Offering

06 дек 2022 18:26:02 Источник Nasdaq GlobeNewswire